hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06340477, orgStudyIdInfo id: Mahnoor Arif/ REC -01802, briefTitle: Effect of Thoracic SNAGS on Vitals Among Individuals With Forward Head Posture, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-07, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Riphah International University, class: OTHER, descriptionModule briefSummary: To determine how vitals (heart rate, blood pressure, respiratory rate, oxygen saturation) and craniovertebral angle will be affected by thoracic SNAGs in individuals with forward head posture., conditionsModule conditions: Neck Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 28, type: ESTIMATED, armsInterventionsModule interventions name: Thoracic SNAGs with conventional therapy, interventions name: conventional therapy, outcomesModule primaryOutcomes measure: Aneroid sphygmomanometer, primaryOutcomes measure: Pulse oximeter, primaryOutcomes measure: Respiratory rate, secondaryOutcomes measure: NPRS (Numeric Pain Rating Scale), secondaryOutcomes measure: Inclinometer, secondaryOutcomes measure: Photogrammetric method for craniovertebral angle, eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Pakistan Railway Hospital, status: RECRUITING, city: Rawalpindi, state: Punjab, zip: 46000, country: Pakistan, contacts name: Maria Khalid, MSOMPT, role: CONTACT, phone: 03315369768, email: maria.khalid@riphah.edu.pk, contacts name: Mahnoor arif, MSOMPT*, role: CONTACT, contacts name: mahnoor arif, MSOMPT*, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 33.6007, lon: 73.0679, hasResults: False
protocolSection identificationModule nctId: NCT06340464, orgStudyIdInfo id: REC.67-018-8-1, briefTitle: Preoperative Nutritional Status Scores to Predict PPC in Elderly With Cardiac Surgery, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-21, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-11-30, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Prince of Songkla University, class: OTHER, descriptionModule briefSummary: This prospective study investigate prognostic values and compare the role of nutritional status by using GNRI, MNA, and PNI in predicting post-operative pulmonary complication among elderly patients with cardiac surgery., conditionsModule conditions: Cardiac Surgery, conditions: Elderly Patient, conditions: Postoperative Pulmonary Complication, conditions: Nutrition Scoring System, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 229, type: ESTIMATED, armsInterventionsModule interventions name: GNRI, PNI, MNA, outcomesModule primaryOutcomes measure: Postoperative pulmonary complication, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Anesthesiology, Faculty of Medicine, Prince of Songkla University, status: RECRUITING, city: Hat Yai, state: Songkhla, zip: 90110, country: Thailand, contacts name: Panalee Kittisopaporn, role: CONTACT, phone: 66832422540, geoPoint lat: 7.00836, lon: 100.47668, hasResults: False
protocolSection identificationModule nctId: NCT06340438, orgStudyIdInfo id: N-20240004 3rd subproject, briefTitle: Investigate the Relationship Between Catastrophizing and the Perception of Itch Intensity in Healthy Individuals, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-27, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Aalborg University, class: OTHER, descriptionModule briefSummary: This project aims to investigate the relationship between different dimensions of catastrophizing (rumination, magnification, and helplessness) as well as some specific personality traits related to catastrophizing tendencies like anxiety sensitivity and fear sensitivity in the modulation of itch and pain intensities in an experimental setting., conditionsModule conditions: Histamine, conditions: Cowhage, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: The participants will randomly receive applications of cowhage and histamine., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: SINGLE, maskingDescription: Participant will be blinded about application of pruritogens., whoMasked: PARTICIPANT, enrollmentInfo count: 46, type: ESTIMATED, armsInterventionsModule interventions name: Histamine, interventions name: Cowhage, outcomesModule primaryOutcomes measure: Reinforcement Sensitivity Theory - Personality Questionnaire (RST-PQ)., primaryOutcomes measure: The Pittsburg Sleep Quality Index (PSQI), primaryOutcomes measure: Depression, Anxiety, Stress Scale (DASS-21), primaryOutcomes measure: Positive And Negative Affect Schedule (PANAS), primaryOutcomes measure: Pain Catastrophizing Scale (PCS)., primaryOutcomes measure: Itch Catastrophizing Scale (ICS)., primaryOutcomes measure: Learned Helplessness Scale (LHS), primaryOutcomes measure: Positive And Negative Affect Schedule (PANAS), primaryOutcomes measure: Depression, Anxiety, Stress Scale (DASS-21), primaryOutcomes measure: Positive And Negative Affect Schedule (PANAS), primaryOutcomes measure: Pain Catastrophizing Scale (PCS)., primaryOutcomes measure: Itch Catastrophizing Scale (ICS)., primaryOutcomes measure: Learned Helplessness Scale (LHS), primaryOutcomes measure: Positive And Negative Affect Schedule (PANAS), secondaryOutcomes measure: Assessment of itch, secondaryOutcomes measure: Assessment of pain, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06340425, orgStudyIdInfo id: s68727, briefTitle: The Effect of Selective Dorsal Rhizotomy on a Multidimensional Outcome Set in Children With Spastic Cerebral Palsy: a Retrospective Study, statusModule overallStatus: COMPLETED, startDateStruct date: 2018-06-26, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2023-12-31, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Universitaire Ziekenhuizen KU Leuven, class: OTHER, descriptionModule briefSummary: Cerebral palsy or CP is the single largest cause of childhood physical disability, with a prevalence of 2-3 per 1000 livebirths. Children with CP experience different primary symptoms, including abnormal increased muscle tone or spasticity. Selective dorsal rhizotomy (SDR) is applied in children with spastic CP as a non-reversible tone reduction procedure. Better understanding of the effects of SDR on a multidimensional outcome set in one CP-cohort and on macroscopic muscle morphology can improve insights and clinical decision making., conditionsModule conditions: Cerebral Palsy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 15, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Overall changes in spasticity, primaryOutcomes measure: Overall change in muscle volume of the medial gastrocnemius, primaryOutcomes measure: Overall changes in muscle length of the medial gastrocnemius, primaryOutcomes measure: Overall changes in muscle cross-sectional area at 50% of muscle belly length, primaryOutcomes measure: Overall changes in gait, primaryOutcomes measure: Overall change in gross-motor function, secondaryOutcomes measure: Overall change of spasticity in the plantar flexors, secondaryOutcomes measure: Overall change of selectivity in the plantar flexors, secondaryOutcomes measure: Overall change of passive range of motion in the ankle and knee joint, secondaryOutcomes measure: Overall change of muscle strength in the plantar flexors, secondaryOutcomes measure: Scatter plots of muscle morphology data (same parameters as for the primary endpoints), eligibilityModule sex: ALL, minimumAge: 5 Years, maximumAge: 16 Years, stdAges: CHILD, contactsLocationsModule locations facility: UZ Leuven, city: Leuven, state: Vlaams-Brabant, zip: 3000, country: Belgium, geoPoint lat: 50.87959, lon: 4.70093, hasResults: False
protocolSection identificationModule nctId: NCT06340399, orgStudyIdInfo id: 202312117RINE, briefTitle: BCAA in Patients Undergoing Gastric Cancer Surgery, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-28, primaryCompletionDateStruct date: 2029-12-31, completionDateStruct date: 2030-12-31, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: National Taiwan University Hospital, class: OTHER, descriptionModule briefSummary: Older patients undergoing gastric cancer resection, at higher risk due to insufficient preoperative muscle mass, are more susceptible to SRML under surgical stress. This not only affects limb muscles but also impacts swallowing muscles, contributing to increased postoperative complications and mortality rates. Enhanced Recovery After Surgery (ERAS) has emerged as a multidisciplinary approach to facilitate postoperative recovery. This study aims to optimize oral nutrition under the ERAS model to observe its impact on SRML. BCAA is essential for skeletal muscles. However, there is limited research on the oral BCAA, whether before or after surgery, concerning SRML and its associated complications. The study entails an 18-month randomized controlled trial with 200 participants. One hundred individuals will take BCAA daily 5 to 14 days before surgery. After surgery, they can progress to a clear liquid diet around postoperative day five while continuing BCAA until 30 days postoperatively. The other one hundred participants will not receive BCAA. The study aims to investigate whether oral BCAA can reduce SRML, muscle loss, and decrease swallowing muscle strength, with observations on postoperative complications and outcomes within one year., conditionsModule conditions: Perioeprative Muscle Loss, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: patients receiving BCAA, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, maskingDescription: this is a open label use study, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: BCAA, interventions name: patient not administered BCAA, outcomesModule primaryOutcomes measure: the occurrence of surgical related muscle loss, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06340386, orgStudyIdInfo id: IEO 1365, briefTitle: Italian Validation of a Tool for Assessing Sexual Function After Breast Cancer, FSFI-BC, statusModule overallStatus: RECRUITING, startDateStruct date: 2020-10-19, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: European Institute of Oncology, class: OTHER, descriptionModule briefSummary: This is a validation study of the italian language for the Female Sexual Function Index-Breast Cancer questionnaire.The validation of the instrument in Italian will allow the identification of possible issues related to sexual health and enable the provision of adequate medical and psychosexual counseling to these patients, both in clinical practice and in research studies., conditionsModule conditions: Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 600, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Validation of the italian translation of Female Sexual Function Index-Breast Cancer questionnaire, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: European Institute of Oncology, status: RECRUITING, city: Milan, country: Italy, contacts name: Gabriella Pravettoni, role: CONTACT, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06340360, orgStudyIdInfo id: 23-358-06, secondaryIdInfos id: 2023-509981-39, type: EUDRACT_NUMBER, briefTitle: A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-27, primaryCompletionDateStruct date: 2025-08-31, completionDateStruct date: 2026-02, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Nektar Therapeutics, class: INDUSTRY, descriptionModule briefSummary: This is an interventional, randomized, double blind, parallel group, placebo-controlled, Phase 2b, 3-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with severe to very severe alopecia areata.The estimated duration includes a screening period of up to 35 days, a 36-week treatment period, and a 24-week follow-up period. The maximum study duration is approximately 65 weeks for all participants., conditionsModule conditions: Alopecia Areata, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Patients will be randomized to 1 of 3 groups (low dose, high dose, or placebo)., primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 110, type: ESTIMATED, armsInterventionsModule interventions name: Rezpegaldesleukin, interventions name: Placebo, outcomesModule primaryOutcomes measure: Percent change from baseline in Severity of Alopecia Tool (SALT) score at Week 36, secondaryOutcomes measure: Percent change from baseline in SALT score, secondaryOutcomes measure: Proportion of patients achieving improvement in Severity of Alopecia Tool (SALT) ≥ 50%/75%/90%, secondaryOutcomes measure: Proportion of patients achieving an absolute SALT score ≤ 10/20/30, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Austin Institute for Clinical Research, status: RECRUITING, city: Pflugerville, state: Texas, zip: 786660, country: United States, geoPoint lat: 30.43937, lon: -97.62, hasResults: False
protocolSection identificationModule nctId: NCT06340347, orgStudyIdInfo id: C5351010, briefTitle: A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver Function, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-24, primaryCompletionDateStruct date: 2026-02-05, completionDateStruct date: 2026-02-05, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Pfizer, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to understand how Osivelotor is processed in people with loss of liver function.This study is seeking participants that are:* stable loss of liver function with mild or moderate severity* none of underlying conditions possibly affecting the study medicine being absorbed by the bodyAll participants will receive one amount of Osivelotor by mouth before breakfast on the first day at the study clinic. A number of blood samples will be collected to understand how Osivelotor is changed and removed from the body. Participants will also have to undergo physical examination and other tests. This will help to understand if Osivelotor is safe.Participants will take part in the study for a maximum of 112 days. During this time, participants will have to stay onsite for 5 days. There will be 5 study visits at the study clinic., conditionsModule conditions: Liver Diseases, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: An open label, single dose, parallel cohort study, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 16, type: ESTIMATED, armsInterventionsModule interventions name: Osivelotor, outcomesModule primaryOutcomes measure: Area under the whole blood and plasma concentration versus time curve (AUC) from time zero (pre-dose) to the last quantifiable concentration (AUClast) of osivelotor, primaryOutcomes measure: Area under the whole blood and plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (AUCinf) of osivelotor, primaryOutcomes measure: Maximum observed whole blood and plasma concentration (Cmax) of osivelotor, secondaryOutcomes measure: Number of Participants With Treatment-Emergent Adverse Events (AEs), secondaryOutcomes measure: Number of Participants With Clinically Significant Laboratory Abnormalities, secondaryOutcomes measure: Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings, secondaryOutcomes measure: Number of Participants With Clinically Significant With Clinically Significant Vital Signs, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06340334, orgStudyIdInfo id: KY20240123-05, briefTitle: Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Nanjing First Hospital, Nanjing Medical University, class: OTHER, descriptionModule briefSummary: To compare the efficacy and safety of Tegoprazan-amoxicillin dual therapy and bismuth quadruple therapy based on furazolidone in the treatment of Helicobacter pylori eradication, the eradication rate, patient compliance, and adverse drug reactions of H. pylori infection were compared in a multi-center clinical joint study in Jiangsu Province., conditionsModule conditions: Helicobacter Pylori Infection, conditions: Tegoprazan, conditions: Furazolidone, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 600, type: ESTIMATED, armsInterventionsModule interventions name: Tegoprazan-amoxicillin dual therapy, outcomesModule primaryOutcomes measure: Helicobacter pylori eradication rate, secondaryOutcomes measure: Security observations, otherOutcomes measure: Patient compliance, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06340321, orgStudyIdInfo id: PBRC 2023-081, briefTitle: Impact of Metabolic Flexibility on Changes in Metabolic Health, acronym: METPROS, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2025-01, completionDateStruct date: 2025-01, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Pennington Biomedical Research Center, class: OTHER, descriptionModule briefSummary: Metabolic flexibility is the capacity to adapt fuel oxidation to fuel availability so that ATP synthesis can match its cellular demands. Thus, for example, increases in glucose availability after a meal would increase glucose oxidation, while increases in lipid availability during fasting would increase lipid oxidation. Enhanced metabolic flexibility has been proposed to protect humans from metabolic diseases. Nevertheless, most studies examining associations between metabolic flexibility and metabolic health outcomes have used cross-sectional designs. Whether impaired metabolic flexibility causes or results from metabolic health impairment is thus unclear.In this study, the investigators will use the data from a study conducted approximately 16 years ago in healthy participants without obesity. Using the data already collected in that study, the metabolic flexibility of each participant will be calculated. To test the association between metabolic flexibility and the change in metabolic health, the investigators will call back all the participants for a single follow-up visit to reassess several metabolic health outcomes. Thus, the main aim of the study is to test the association between metabolic flexibility and the change in metabolic health outcomes after 16 years in humans., conditionsModule conditions: Obesity, conditions: Metabolic Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 88, type: ESTIMATED, armsInterventionsModule interventions name: Metabolic flexibility in the fasted state, interventions name: Metabolic flexibility in euglycemic-hyperinsulinemic clamp, interventions name: Metabolic flexibility in the metabolic chamber, outcomesModule primaryOutcomes measure: Glucose, primaryOutcomes measure: Total cholesterol, primaryOutcomes measure: HDL cholesterol, primaryOutcomes measure: LDL cholesterol, primaryOutcomes measure: Triglycerides, primaryOutcomes measure: HOMA-IR, primaryOutcomes measure: Blood pressure, primaryOutcomes measure: Waist circumference, primaryOutcomes measure: Body mass index, primaryOutcomes measure: Body fat percentage, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Pennington Biomedical Research Center, city: Baton Rouge, state: Louisiana, zip: 70808, country: United States, geoPoint lat: 30.45075, lon: -91.15455, hasResults: False